z-logo
Premium
Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL‐60) by compounds which induce differentiation of murine leukemia cells
Author(s) -
Collins S. J.,
Bodner A.,
Ting R.,
Gallo R. C.
Publication year - 1980
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910250208
Subject(s) - leukemia , cellular differentiation , biology , cell culture , k562 cells , myeloid , myeloid leukemia , cancer research , microbiology and biotechnology , immunology , biochemistry , gene , genetics
Various compounds active in promoting in vitro differentiation of certain murine leukemia cell lines (Friend erythroleukemia cells and mouse myeloid leukemia cells) were tested for their capacity to induce differentiation of HL‐60 cells, a human promyelocytic leukemia cell line capable of terminally differentiating in vitro to functionally mature granulocytes. Polar planar compounds including hexamethylene bisacetamide (HMBA), certain purines (particularly hypoxanthine), and actinomycin‐D induced morphological and functional (as assessed by the capacity to reduce NBT dye) differentiation of HL‐60. In contrast, hemin, ouabain, prostaglandin E 1 , X‐irradiation, dexamethasone and some other anti‐leukemic chemotherapeutic agents induced little if any significant differentiation of HL‐60 cells. These results, together with previous observations with murine leukemia cells, suggest that the human HL‐60 cells share common cellular target sites for the inducing action of polar planar compounds, hypoxanthine and actinomycin‐D with some murine leukemic cells. In contrast, hemin, ouabain and prostaglandin E, may be specific for mouse erythroleukemia cells, while X‐irradiation and chemotherapeutic agents induce differentiation of both types (erythroid and myeloid) of mouse leukemic cells, but have little effect on HL‐60 cells.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here